Skip to main content
padlock icon - secure page this page is secure

Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies

Buy Article:

$68.00 + tax (Refund Policy)

Generalized epilepsies are a large group of epilepsies with different clinical aspects and prognosis. Many antiepileptic drugs are available for the treatment of these seizures. This paper reviews the evidence relating to the treatment of this group of epilepsies.

Historically, the great majority of patients have been treated with “old” anticonvulsant drugs.

Over recent years, there has been a marked improvement in the pharmacological armamentarium of physicians. Today, “new” antiepileptic drugs, such as lamotrigine, levetiracetam, topiramate and zonisamide are useful tools in the treatment of pharmacoresistant epilepsies.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Epileptic patients; epilepsy; new antiepileptics; old antiepileptics

Document Type: Research Article

Publication date: September 1, 2007

More about this publication?
  • Current Clinical Pharmacology publishes frontier reviews on all the latest advances in clinical pharmacology. The journal's aim is to publish the highest quality review articles in the field. Topics covered include: pharmacokinetics; therapeutic trials; adverse drug reactions; drug interactions; drug metabolism; pharmacoepidemiology; and drug development. The journal is essential reading for all researchers in clinical pharmacology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more